SAM
ALXO icon

Shell Asset Management’s ALX Oncology ALXO Stock Holding History

Shell Asset Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,333
Closed -$201K – 1451
2020
Q4 		$201K Buy
+2,333
New +$140K ﹤0.01% 1115

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shell Asset Management's ALXO Position: Q1 2021 in Review

Shell Asset Management sold out of ALX Oncology (ALXO) in Q1 2021, closing a stake of 2,333 shares — an estimated $201K sold.

Shell Asset Management first reported a position in ALXO in Q4 2020 and held it in 1 quarter. The position peaked at $201K in Q4 2020. 93 funds tracked by Wall St. Rank hold ALXO as of Q1 2021.

  • Shell Asset Management reported no remaining ALX Oncology position as of Q1 2021 after selling out during the quarter.
  • Shell Asset Management sold 2,333 ALX Oncology shares in Q1 2021, an estimated $201K.
  • Shell Asset Management first reported a position in ALX Oncology in Q4 2020 and held it in 1 quarter.
  • Shell Asset Management's ALX Oncology position peaked at $201K in Q4 2020.
  • 93 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.